LMR Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

LMR Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-524,772	Closed	-$96.4M	–	1345
2021 Q2	$96.4M	Buy	524,772 +42,747	+9%	+$7.34M	1.46%	7
2021 Q1	$73.7M	Buy	482,025 +398,980	+480%	+$61.7M	1.84%	4
2020 Q4	$13M	Sell	83,045 -77,140	-48%	-$9.91M	0.2%	56
2020 Q3	$18.3M	Buy	160,185 +63,637	+66%	+$6.87M	0.38%	33
2020 Q2	$10.8M	Sell	96,548 -26,230	-21%	-$2.78M	0.27%	61
2020 Q1	$10.7M	Buy	+122,778	New	+$12M	0.5%	53
2019 Q4	–	Sell	-64,978	Closed	-$6.36M	–	610
2019 Q3	$6.36M	Buy	64,978 +42,683	+191%	+$4.81M	0.31%	53
2019 Q2	$2.92M	Buy	+22,295	New	+$2.87M	0.11%	93
2017 Q3	–	Sell	-3,119	Closed	-$379K	–	619
2017 Q2	$379K	Sell	3,119 -4,525	-59%	-$527K	0.02%	442
2017 Q1	$927K	Buy	+7,644	New	+$986K	0.09%	134
2016 Q3	–	Sell	-17,417	Closed	-$2.03M	–	529
2016 Q2	$2.03M	Buy	+17,417	New	+$2.47M	0.32%	96
2015 Q3	–	Sell	-7,629	Closed	-$1.38M	–	539
2015 Q2	$1.38M	Buy	7,629 +3,071	+67%	+$530K	0.17%	175
2015 Q1	$790K	Sell	4,558 -1,309	-22%	-$237K	0.11%	224
2014 Q4	$1.09M	Buy	+5,867	New	+$1.09M	0.14%	194
2014 Q3	–	Sell	-21,179	Closed	-$3.31M	–	510
2014 Q2	$3.31M	Buy	+21,179	New	+$3.34M	0.28%	94

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

LMR Partners's ALXN Position: Q3 2021 in Review

LMR Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 524,772 shares — an estimated $96.4M sold.

LMR Partners first reported a position in ALXN in Q2 2014 and held it in 15 quarters. The position peaked at $96.4M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

LMR Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 524,772 Alexion Pharmaceuticals shares in Q3 2021, an estimated $96.4M.
LMR Partners first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 15 quarters.
LMR Partners's Alexion Pharmaceuticals position peaked at $96.4M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.